Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy adults
NCT05184452Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of PGDM1400LS in human immunodeficiency virus infection (HIV) (10 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness at Day 112, Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration at Day 112 and 13 more. Started Nov 2021; status: completed.
02
Drugs
PGDM1400LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05184452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184452.